Our Consortium proposes to build on this program for biochemical, immunologic and gene polymorphism assessment of patients with an enriched Consortium of European, Egyptian and Tunisian academic institutions and one European SME. Our multi-national, inter-disciplinary Consortium is in a strong position to establish an in-depth understanding of spontaneous viral clearance and provide needed information that will impact patient management and the design of candidate vaccines for HCV genotype 4.
Sphinx main objectives are :
- To maintain the follow up of acutely infected symptomatic HCV patients and establish a new prospective collection of samples for use in identification and validation of biomarkers of spontaneous viral clearance.
- To utilize an “–omics” approach to determine which plasma analytes and cellular immune system activation parameters correlate with viral clearance.
- To identify genetic determinants of viral clearance using candidate-gene approaches and genome-wide association studies.
- Provide training opportunities for scientists within the Consortium and associated MPCs
- To establish synergistic collaboration between European (EU-funded HepaCute and SPHINX projects) and Egyptian STDF funded (the Science and Technology Development Fund) research programmes on HCV and HCV patient management and to build research capacity.
Sphinx main public health impacts are :
- To improve on existing standard treatments.
- To be able to propose alternative treatments.
- To improve HCV patients daily life.
- To candidate vaccines for HCV genotype 4.